MTNR1B rs10830963基因多态性对瑞格列奈治疗2型糖尿病患者疗效的影响被引量：4

Effects of MTNR1B rs10830963 polymorphism on repaglinide response in patients with type 2 diabetes mellitus

下载PDF

导出

摘要目的:研究MTNR1B rs10830963基因多态性对瑞格列奈治疗2型糖尿病(T2DM)患者疗效的影响。方法:选取新诊断的T2DM患者90例,口服瑞格列奈1 mg,一日3次,连续8周,服药前和服药第8周末收集静脉血标本,测定治疗前后人体参数及糖脂代谢相关指标。采用高分辨溶解曲线方法对患者进行MTNR1B rs10830963基因分型。结果:80例患者完成8周随访,CG+GG基因型携带者空腹血糖(FPG)下降幅度、胰岛β细胞功能指数(HOMA-β)升高幅度均小于CC野生型携带者(P<0.05)。结论:MTNR1B rs10830963基因变异与瑞格列奈治疗T2DM的疗效相关,CC基因型携带者疗效更好。 AIM： To investigate the effects of MTNR1 B rs10830963 polymorphism on repaglinide response in patients with type 2 diabetes mellitus（ T2DM）. METHODS： Ninety newly-diagnosed patients with T2 DM were orally administrated 1 mg repaglinide three times per day for 8 consecutive weeks. The venous blood samples were collected at0 and 8th weekend. Anthropometric measurements and the parameters of glucose and lipid metabolism were determined before and after repaglinide treatment. The patients were enrolled to identify genotypes for MTNR1 B rs10830963 by the method of high resolution of melting curve. RESULTS： Eighty patients accomplished the 8-week follow-up visits.The reduction in FPG levels and increase in HOMA-β were lower in the carriers of genotype CG ＋ GG at rs10830963 than those with the wild-type CC（ P〈0. 05）. CONCLUSION： The MTNR1 B rs10830963 polymorphism was associated with therapeutic efficacy of repaglinide in T2 DM patients. The CC homozygotes had a better effect than G allele carriers.

作者王涛吕冬梅王艳宋金方鲁茜张帆李伟印晓星

机构地区徐州医学院附属医院药学部江苏省新药研究与临床药学重点实验室徐州医学院药学院临床药理学教研室徐州医学院附属医院内分泌科

出处《中国临床药理学与治疗学》 CAS CSCD 2015年第8期933-937,共5页 Chinese Journal of Clinical Pharmacology and Therapeutics

基金徐州市科技计划项目(Y3105)

关键词 MTNR1B rs10830963 基因多态性 2型糖尿病瑞格列奈 MTNR1B rs10830963 genetic polymorphism type 2 diabetes mellitus repaglinide

分类号 R969 [医药卫生—药理学]

引文网络
相关文献

参考文献12

1Bouatia-Naji N, Bonnefond A, Cavalcanti-Proenca C, et al. A variant near MTNR1 B is associated with increased fasting plasma glucose levels and type 2 diabetes risk[J]. Nat Genet, 2009, 41 (1) : 89-94.
2Lyssenko V, Nagoruy CLF, Erdos MR, et al. Com- mon variant in MTNRI B associated with increased risk of type 2 diabetes and impaired early insulin secretion[J]. Nat Genet, 2009, 41 (1) : 82-88.
3Prokopenko I, Langenberg C, FlorezJC, et al. Variants in MTNRI B infiuence fasting glucose levels[J] . Nat Genet, 2009,41(1): 77-81.
4Kan MY, Zhou DZ, Zhang D, et al. Two susceptible diabetogenic variants near/in MTNRI B are associated with fasting plasma glucose in a Han Chinese cohort[J]. Diabet Med, 2010, 27(5) :598-602.
5Liu C, Wu Y, Li H, et al. MTNRIB rs10830963 is associated with fasting plasma glucose, HbAI C and impaired beta-cell function in Chinese Hans from Shanghai[J]. BMC Med Genet, 2010,11:1-7.
6Yu W, Hu C,Jia W, et al. Genetic advances of type 2 diabetes in Chinese populations[J].J Diabetes, 2012, 4 (3) : 213-220.
7WangT, WangY, LvDM, etal. Effects of NOS1AP rs12742393 polymorphism on repaglinide response in Chinese patients with type 2 diabetes mellitus[J] . Pharmacotherapy, 2014, 34(2) :131-139.
8Yu M, Xu XJ, YinJY, et al. KCNJ11 Lys23Glu and TCF7 L2 rs290487 ( C/T) polymorphisms affect therapeutic efficacy of repaglinide in Chinese patients with type 2 diabetes[J]. Clin Pharmacol Ther, 2010, 87 (3) : 330-335.
9Peschke E, Bach AG, Muhlbauer E. Parallel signaling pathways of melatonin in the pancreatic beta-cell[J].J Pineal Res, 2006, 40( 2) : 184-19l.
10Stumpf I, Bazwinsky I, Peschke E. Modulation of the cGMP signaling pathway by melatonin in pancreatic beta-cells[J] ,J Pineal Res, 2009, 46(2) :140-147.